Cartesian Therapeutics AI Stock Analysis
Want to see RNAC full AI Analyst Report?
Cartesian Therapeutics (RNAC) AI Stock Analysis
Cartesian Therapeutics
(NASDAQ:RNAC)
The score is held down primarily by weak financial performance (shrinking revenue, large losses, and significant cash burn alongside negative equity). Technicals are also mixed-to-weak with the stock below key longer-term moving averages and a negative MACD. A notable offset is the positive corporate event around Descartes-08 retreatment data, but valuation support is limited given the company is loss-making and no dividend yield is provided.
Cartesian Therapeutics (RNAC) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $185.46M
- Dividend Yield
- ―
- Average Volume (3M)
- 137.37K
- Price to Earnings (P/E)
- -1.2
- Beta (1Y)
- 2.54
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- US
- Employees
- 75
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Cartesian Therapeutics Business Overview & Revenue Model
Company Description
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cel...
How the Company Makes Money
Cartesian Therapeutics is a pre-commercial, clinical-stage biotechnology company. As of publicly available information up to my knowledge cutoff (2025-08), it does not have an approved product and therefore does not generate recurring product sales r...
Cartesian Therapeutics Financial Statement Overview
Summary
Weak fundamentals driven by steep revenue decline into TTM, heavy sustained losses (TTM net loss ~$129.5M), and significant ongoing cash burn (TTM operating cash flow about -$88.7M and negative free cash flow). Balance sheet is constrained by negative equity (TTM ~-$130.5M), increasing financing/dilution risk despite relatively modest absolute debt (~$10.1M TTM).
Income Statement
22NegativeBalance Sheet
28NegativeCash Flow
24Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.02M | 2.80M | 38.91M | 26.00M | 110.78M | 85.08M |
| Gross Profit | 1.02M | 2.80M | 38.91M | 26.00M | 108.74M | 85.08M |
| EBITDA | -130.78M | -136.54M | -75.99M | -235.03M | 39.09M | -5.63M |
| Net Income | -129.51M | -130.30M | -77.42M | -219.71M | 35.38M | -25.69M |
Balance Sheet | ||||||
| Total Assets | 294.31M | 296.41M | 435.02M | 305.05M | 165.89M | 159.88M |
| Cash, Cash Equivalents and Short-Term Investments | 122.97M | 125.14M | 212.61M | 76.91M | 134.60M | 128.06M |
| Total Debt | 60.34M | 12.68M | 13.98M | 10.96M | 37.92M | 35.28M |
| Total Liabilities | 424.77M | 422.65M | 441.82M | 745.23M | 72.06M | 137.36M |
| Stockholders Equity | -130.47M | -126.24M | -6.80M | -440.18M | 93.83M | 22.52M |
Cash Flow | ||||||
| Free Cash Flow | -89.44M | -79.39M | -32.77M | -51.37M | -32.83M | -61.47M |
| Operating Cash Flow | -88.20M | -73.94M | -23.67M | -51.16M | -31.63M | -60.38M |
| Investing Cash Flow | -1.23M | -5.45M | -8.74M | 34.61M | -15.00M | -17.14M |
| Financing Cash Flow | 53.85M | -8.05M | 168.43M | -13.14M | 39.22M | 52.90M |
Cartesian Therapeutics Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RNAC, the sentiment is Negative. The current price of 6.08 is below the 20-day moving average (MA) of 6.58, below the 50-day MA of 7.08, and below the 200-day MA of 7.61, indicating a bearish trend. The MACD of -0.15 indicates Positive momentum. The RSI at 38.57 is Neutral, neither overbought nor oversold. The STOCH value of 9.47 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for RNAC.
Cartesian Therapeutics Risk Analysis
Cartesian Therapeutics disclosed 47 risk factors in its most recent earnings report. Cartesian Therapeutics reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
3 New RisksCartesian Therapeutics Peers Comparison
Overall Rating
CLLS49Neutral
IPSC49Neutral
RNAC47Neutral
FATE45Neutral
NKTX44Neutral
CABA41Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 49Neutral | $79.50M | -1.68 | -94.14% | ― | -0.11% | -13.99% | |
| 49Neutral | $297.82M | -2.19 | -45.64% | ― | -100.00% | -97.48% | |
| 47Neutral | $185.46M | -1.24 | 97.73% | ― | ― | ― | |
| 45Neutral | $138.59M | -1.09 | -73.92% | ― | -33.45% | 21.90% | |
| 44Neutral | $86.76M | -0.70 | -48.58% | ― | ― | -24.79% | |
| 41Neutral | $239.45M | -0.78 | -106.78% | ― | ― | 43.51% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| RNAC | Cartesian Therapeutics, Inc. | 6.08 | -1.54 | -20.21% | |
| FATE | Fate Therapeutics Inc | 1.14 | 0.12 | 11.76% | |
| CLLS | Cellectis S.A. | 1.04 | -3.07 | -74.70% | |
| CABA | Cabaletta Bio, Inc. | 1.11 | -1.23 | -52.56% | |
| NKTX | Nkarta, Inc. | 1.21 | -0.60 | -33.15% | |
| IPSC | Century Therapeutics, Inc. | 1.64 | 1.15 | 234.69% |
Cartesian Therapeutics Corporate Events
Cartesian Therapeutics Reports Encouraging Descartes-08 Retreatment Data
PositiveOn September 29, 2026, Cartesian Therapeutics reported additional retreatment data from its Phase 2 trial of Descartes-08 in patients with generalized myasthenia gravis. In five patients who experienced symptom recurrence at least 12 months after an...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 05, 2026
